The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
April 14, 2025
View Complete Issue         Table of Contents 2019 
Vimseltinib (Romvimza) for Tenosynovial Giant Cell Tumor (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vimseltinib (Romvimza) for Tenosynovial Giant Cell Tumor (online only)
April 14, 2025 (Issue: 1726)
Vimseltinib (Romvimza – Deciphera), an oral kinase inhibitor, has been approved by the FDA for treatment of symptomatic tenosynovial giant cell tumor in adults for whom surgical resection would cause worsening functional limitation or severe...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Vimseltinib (Romvimza) for Tenosynovial Giant Cell Tumor (online only)
Article code: 1726h
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.